Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching lupus stem cell therapy China may encounter UC-MSC therapy as an emerging treatment approach for systemic lupus erythematosus (SLE), including lupus nephritis. In China, this treatment is available through a supervised medical-access pathway at a designated hospital in the Hainan Boao Lecheng International Medical Tourism Pilot Zone. This guide explains what the treatment is, its current access pathway, eligibility considerations, estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is UC-MSC Therapy for Lupus?
UC-MSC therapy uses umbilical cord-derived mesenchymal stem cells (UC-MSCs). The treatment is designed to regulate immune-system balance by inhibiting excessive immune activation.
For patients researching lupus stem cell therapy China, the relevant indication is systemic lupus erythematosus, including multi-system involvement such as lupus nephritis. The treatment approach is intended to address immune-system activity associated with SLE rather than being described simply as symptomatic treatment.
Efficacy and safety remain under evaluation. The available treatment information does not establish a cure or guarantee an individual outcome.
Is Lupus Stem Cell Therapy Available in China?
Yes. Lupus stem cell therapy China is available through the Hainan Boao Lecheng International Medical Tourism Pilot Zone's supervised medical-access pathway at the designated hospital.
This access pathway is different from nationwide regulatory approval. Availability within the Lecheng pilot zone means the treatment can be provided under the applicable licensed hospital pathway; it should not be interpreted as approval for routine use throughout mainland China.
Patients should also understand that the treatment's efficacy and safety remain under evaluation and that treatment access remains subject to medical assessment.
Where Is Lupus Stem Cell Therapy Offered in China?
The treatment is offered at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in Hainan.
Technical support is provided by Shenzhen Beike Biotechnology Co., Ltd. The treatment uses umbilical cord-derived mesenchymal stem cells.
Who May Be Eligible for Lupus Stem Cell Therapy?
The treatment is indicated for patients with systemic lupus erythematosus (SLE), including lupus nephritis. Detailed additional eligibility criteria are not specified, so an indication alone does not determine whether an individual patient can receive treatment.
Patients considering lupus stem cell therapy China should have their medical records reviewed by the treating team, particularly records documenting the diagnosis and current management of SLE or lupus nephritis.
Final eligibility is determined by the treating medical team after a face-to-face consultation or review of the patient's medical records.
How Much Does Lupus Stem Cell Therapy Cost in China?
For international patients, the estimated cost is ¥135,000 (approximately US$18,800) per session. Domestic patients have a stated price of ¥60,000 per session.
The USD figure uses an approximate exchange rate of ¥7.18 per US$1 and is provided as a reference conversion.
The stated treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or international travel. Confirm final pricing and the full scope of costs directly with the hospital before making travel arrangements.
Why International Patients May Consider Lupus Stem Cell Therapy China
For some international patients, China's supervised access pathway may provide another option to discuss with specialists when exploring treatment approaches for SLE, including lupus nephritis.
The key consideration is the distinction between access and established efficacy. The availability of UC-MSC therapy in the Lecheng pilot zone does not by itself demonstrate that the treatment is more effective than established lupus management, and safety and efficacy remain under evaluation.
International patients can therefore use the access pathway as an opportunity to obtain a specialist assessment and understand whether the treatment is medically appropriate for their individual circumstances.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and systemic lupus erythematosus-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering Lupus Stem Cell Therapy China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is lupus stem cell therapy available in China?
Yes. Lupus stem cell therapy is available through the Hainan Boao Lecheng pilot-zone pathway at Hainan Haikong Le City Hospital. This does not mean the treatment has nationwide approval in China.
How much does lupus stem cell therapy cost in China?
For international patients, the estimated cost is ¥135,000 (approximately US$18,800) per session. Confirm the final price and what it includes directly with the hospital.
Who may qualify for UC-MSC therapy for lupus?
The treatment is indicated for systemic lupus erythematosus, including lupus nephritis. Detailed individual eligibility criteria are not specified, and final eligibility requires assessment by the treating medical team.
Can international patients explore lupus stem cell therapy in China?
Yes. International patients can explore the treatment through the designated hospital's access pathway, subject to medical evaluation and eligibility review.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
